Global Emphysema Treatment Market Size and Forecast 2024-2033|AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC

The Emphysema Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Emphysema Treatment Market:

https://www.thebusinessresearchcompany.com/report/emphysema-treatment-global-market-report

According to The Business Research Company’s Emphysema Treatment Global Market Report 2024, The emphysema treatment market size has grown strongly in recent years. It will grow from $4.96 billion in 2023 to $5.29 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%. The  growth in the historic period can be attributed to smoking epidemic impact, advancements in medications, pulmonary rehabilitation programs, improved diagnostic tools, awareness and education.

The emphysema treatment market size is expected to see strong growth in the next few years. It will grow to $6.85 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to aging population trends, customized treatment approaches, expanded access to therapies, focus on symptom management, collaborative healthcare models.. Major trends in the forecast period include exploration of gene therapies, patient education and empowerment, integration of artificial intelligence (ai), increased accessibility to treatment, long-acting medications development.

The rise in the prevalence of chronic obstructive pulmonary disease (COPD) cases is expected to propel the growth of the emphysema treatment market going forward. Chronic obstructive pulmonary disease (COPD) is a set of disorders that cause airflow obstruction and breathing difficulties, including emphysema and chronic bronchitis. Emphysema therapies are essential in reducing the advancement of Chronic Obstructive Pulmonary Disease (COPD) as they focus on treating symptoms, restoring lung function, and delaying disease progression. For instance, in September 2021, according to the study released by the Forum of International Respiratory Societies, a Switzerland-based respiratory health advocacy organization, an estimated 200 million people have COPD in 2021, with around 3.2 million dying each year, making it the third-leading cause of mortality globally. Therefore, the rise in the prevalence of chronic obstructive pulmonary disease (COPD) cases drives the emphysema treatment market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=10807&type=smp

The emphysema treatment market covered in this report is segmented –

1) By Treatment: Smoking Cessation, Bronchodilators, Steroids, Leukotriene Modifiers, Supplemental Oxygen, Antibiotics, Gene Therapy, Surgery Transplant, Other Treatments

2) By Distribution Channel: Online Providers, Drug Stores and Retail Pharmacies, Hospital Pharmacies

3) By End-User: Clinics, Surgical Centre, Other End-Users

Major companies operating in the emphysema market are developing minimally invasive procedures for emphysema patients to gain a competitive edge in the market. Minimally invasive procedures refer to medical interventions or surgical techniques that are performed with minimal disruption to the body’s normal structures. For instance, in January 2022, Adena Health System, a US-based healthcare company, launched the Zephyr Valve surgery. It is a minimally invasive procedure that offers an alternative to conventional lung volume reduction surgery for individuals experiencing lung hyperinflation, a common issue in emphysema and COPD. This innovative approach involves placing small, one-way Zephyr Valves in the airways of the lungs via a bronchoscope. These valves facilitate the release of trapped air, preventing further accumulation, and allowing healthier lung areas to expand, thereby improving breathing.

The emphysema treatment market report table of contents includes:

1. Executive Summary

2. Emphysema Treatment Market Characteristics

3. Emphysema Treatment Market Trends And Strategies

4. Emphysema Treatment Market – Macro Economic Scenario

5. Global Emphysema Treatment Market Size and Growth

.

.

.

26. South America Emphysema Treatment Market

27. Brazil Emphysema Treatment Market

28. Middle East Emphysema Treatment Market

29. Africa Emphysema Treatment Market

30. Emphysema Treatment Market Competitive Landscape And Company Profiles

Top Major Players:

  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd
  • Novartis AG
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: [email protected]

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model